Hypomagnesemia with secondary hypocalcemia
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Hypomagnesemia with secondary hypocalcemia Classification and external resources | |
| OMIM | 602014 |
|---|---|
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Hypomagnesemia with secondary hypocalcemia (HSH) is an autosomal recessive genetic disorder affecting intestinal magnesium absorption. Decreased intestinal magnesium reabsorption and the resulting decrease in serum magnesium levels is believed to cause lowered parathyroid hormone (PTH) output by the parathyroid gland. This results in decreased PTH and decreased serum calcium levels (hypocalcemia). This manifests in convulsions and spasms in early infancy which, if left untreated, can lead to mental retardation or death. HSH is caused by mutations in the TRPM6 gene.
Diagnosis
Diagnosis typically occurs during the first 6 months of life due to characteristic neurological symptoms. These symptoms include muscle spasms, tetany, and seizures. Laboratory testing indicates hypomagnesemia (decreased serum magnesium levels), hypocalcemia (decreased serum calcium levels), and little to no measurable parathyroid hormone levels. Diagnosis is confirmed with these symptoms and can be further solidified with genetic sequencing of the TRPM6 gene.
Pathophysiology
HSH is caused by decreased intestinal magnesium reabsorption through TRPM6 channels. When expressed in cells, TRPM6 produces outwardly rectifying currents with the outward portion comprised of Na+ ions and the inward portion of divalent cations (particularly magnesium and calcium). Inward flow of sodium ions is blocked by extracellular divalent cations. Increased intracellular magnesium concentrations also decrease current through TRPM6 channels. There are currently more than 30 known mutations in TRPM6 that are associated with HSH and these mutations are spreading throughout the gene (table 1). Of the eight HSH mutations that have been tested, none have shown to produce whole-cell current. The S141L mutation, one of the few missense mutations, has been of particular interest to researchers. They have found that it prevents coassembly with TRPM7 (and presumably other TRPM6 subunits) and lacks the ability to traffic to the membrane. Whether other mutants are able to traffic properly to the surface or coassemble has not yet been further studied.
While the hypomagnesemia in patients with HSH is a direct result of TRPM6 mutations, hypocalcemia is an indirect, secondary result. Parathyroid gland secretion of PTH can be altered by changes in serum magnesium levels. The decreased serum magnesium levels seen in HSH result in decreased PTH secretion. PTH, in turn, controls the availability of serum calcium. Decreasing PTH levels cause a decrease in calcium availability in serum and, thus, the neurological symptoms of HSH.
| Mutation | Location | Functional? | Reference | |
|---|---|---|---|---|
| Nucleotide | Amino Acid | |||
| c.C166T | R56X | N-terminus | [1] | |
| c.C422T | S141L | N-terminus | No | [1],[1],[1],[1] |
| c.G469T | E157X | N-terminus | [1] | |
| c.T521G | I174R | N-terminus | [1] | |
| c.668delA | D223fsX263 | N-terminus | [1] | |
| c.1010+5G→C | Splicing | N-terminus | [1] | |
| c.A1060C | T354P | N-terminus | [1] | |
| c.1134+5G→A | Splicing | N-terminus | [1] | |
| c.1208-1G→A | Splicing | N-terminus | [1] | |
| c.1280delA | H427fsX429 | N-terminus | No | [1],[1] |
| c.1308+1G→A | Splicing | N-terminus | [1] | |
| c.C1437A | Y479X | N-terminus | [1] | |
| c.C1450T | R484X | N-terminus | [1] | |
| c.C1769G | S590X | N-terminus | No | [1],[1],[1] |
| c.del1796-1797 | P599fsX609 | N-terminus | [1] | |
| c.2009+1G→A | Splicing | N-terminus | [1],[1] | |
| c.G2120A | C707Y | N-terminus | [1] | |
| c.2207delG | R736fsX737 | N-terminus | No | [1],[1],[1] |
| c.2537-2A→T | Splicing | N-terminus | [1] | |
| c.2667+1G→A | Splicing | [1],[1] | ||
| c.C2782T | R928X | M3 | No | [1] |
| c.del Ex 21 | M4 | [1] | ||
| c.Del2831-2832insG | I944fsX959 | M4-M5 | [1] | |
| c.3209-68A→G | Splicing | [1] | ||
| c.del Ex 22 + 23 | M5-6 | [1] | ||
| C.3537-1G→A | Splicing | [1],[1] | ||
| c.3779-91del | Q1260fsX1283 | C-terminus | [1],[1] | |
| c.del Ex 25 - 27 | C-terminus | [1] | ||
| c.del Ex 26 | Y1533X | C-terminus | No | [1] |
| c.5017-18delT | L1673fsX1675 | C-terminus | No | [1] |
| c.del Ex 31 + 32 | C-terminus | No | [1] | |
| c.5057+2T→C | Splicing | C-terminus | [1] | |
| c.A5775G | Splicing | C-terminus | [1] | |
Treatment
Treatment of HSH involves administration of high doses of magnesium salts. These salts may be taken orally or otherwise (e.g. subcutaneously). This treatment works by increasing magnesium absorption through the non-TRPM6 mediated paracellular uptake pathways. This treatment must be continued throughout life.
History
HSH was originally believed to be an X-linked disorder due to the preponderance of affected males. With the finding that mutations in TRPM6 (on chromosome 9) are causative for the disorder this is no longer the case. Of recent interest, however, is the characterization of a patient with symptoms similar to HSH who has a translocation of the chromosomes 9 and X.[1]
See also
References
- Konrad M, Schlingmann K, Gudermann T (2004). "Insights into the molecular nature of magnesium homeostasis.". Am J Physiol Renal Physiol 286 (4): F599-605. PMID 15001450.
Footnotes
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
